Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874222 · ClinicalTrials.gov registry record
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms
A clinical trial, sponsored by United States Naval Medical Center, San Diego.
- Completed
- Registry status
- 13
- Enrollment target
NCT02874222 is a clinical trial that has completed, run by United States Naval Medical Center, San Diego. The registered enrollment target is 13 participants.
The verdict
NCT02874222 has completed, sponsored by United States Naval Medical Center, San Diego.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
Breast cancer is one of the most prevalent cancers with 207,090 new cases of breast cancer and 39,840 deaths in women predicted for 2010 in the United States. Aromatase inhibitors (AIs) are used as first-line adjuvant therapy for postmenopausal women with early stage breast cancer. The effectiveness of current therapy is widely recognized to be compromised by poor compliance because of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), a syndrome that affects up to 40-50% of women who take these medications. The syndrome that was not recognized during the registration trials for this class of drugs, it can lead to discontinuation in up to 24% of women over 2 years. Knowledge that can be used to prevent discontinuation of these important agents because of severe AIMSS is urgently needed.
Interventions
- OTHER surveys completed by subject
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-05 |
| Est. Completion | 2024-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874222
The ClinicalTrials.gov registry entry for NCT02874222 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United States Naval Medical Center, San Diego, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which surveys completed by subject is the first listed.
NCT02874222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874222 about?
NCT02874222 is a clinical study titled "A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms". Breast cancer is one of the most prevalent cancers with 207,090 new cases of breast cancer and 39,840 deaths in women predicted for 2010 in the United States. Aromatase inhibitors (AIs) are used as first-line adjuvant therapy for postmenopausal women with early stage breast cancer. The effectiveness...
What is the current status of trial NCT02874222?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2015-05. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT02874222?
The interventions under investigation include: surveys completed by subject (OTHER).
Who is sponsoring clinical trial NCT02874222?
This trial is sponsored by United States Naval Medical Center, San Diego, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.